ClinicalTrials.gg
CompletedNCT00694057Updated Jun 14, 2011

Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

A Phase 2 interventional study of HE3286 and Placebo in Type 2 Diabetes Mellitus, sponsored by Harbor Therapeutics. Completed at 22 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2011-06-14.

Sponsored by Harbor Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
164
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States — 343 open to participants now, 478 under way, 51 of them phase 3. Diabetes Mellitus, Type 2 · United States.

Enrollment
1,106th of 2,957
164 · median 90
Started
2008
with 166 others
Phase 2
391 of 3,304
24 open now
Registered
532nd of 3,304
by date

Among the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, this one is the 1,106th largest by enrollment of the 2,957 interventional ones that give a count, is one of 167 that started in 2008, is one of 391 in phase 2, and was the 532nd registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

343 of the 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States are open now. Recruiting first, the newest first:

338 more — sign in →

All 343 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 3,304 studies in Diabetes Mellitus, Type 2 with a site in United States, or all of them as a file.
02

Study summary

This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-weeks.

Read the detailed description

Hollis-Eden Pharmaceuticals, Inc. is developing a new class of therapeutics for the treatment of Type 2 diabetes. The investigational drug, HE3286, holds the potential to be the first in a new class of insulin sensitizers with a potentially novel mechanism of action that may improve the current therapeutic options available to a T2DM patient.

This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-weeks. Changes in hemoglobin A1c (HbA1c) will be assessed over a treatment period of 12-weeks.

03

Conditions studied

  • Type 2 Diabetes Mellitus

Keywords

  • Type 2 Diabetes Mellitus
  • Metformin
  • HbA1c
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Main Inclusion Criteria:

  • Patient with a diagnosis of Type 2 Diabetes Mellitus (T2DM)
  • Patient must be a) on a stable dose of metformin as monotherapy for at least 10 weeks prior to screening; or b) drug-naive, defined as never having received drug treatment for T2DM or not having received antidiabetic drug therapy during the 3 months prior to screening.
  • Patient with a fasting blood glucose level of ≤ 225 mg/dL at screening (≤ 255 mg/dl for drug-naive patients);
  • Patient with levels >7.5% (7.0 - 10.5% for drug-naive patients) at screening;
  • Patient with 28-37 kg/m2 for females 28-39 kg/m2 for males

Main Exclusion Criteria:

  • Patient who has a history of cardiovascular disease (including coronary artery disease), clinically significant hepatic, respiratory or renal abnormalities within 6 months prior to screening;
  • Patient with unstable diabetic complications requiring treatment or ongoing active intervention;
  • Patient with a history of long term insulin therapy within the past year;
  • Patient who has had therapy with rosiglitazone, pioglitazone, exendin-4 or sitagliptin, alone or in combination within 6 months prior to screening;
  • Patient who has any clinically significant abnormalities in laboratory results at screening;
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
164 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo capsules BID

    Drug: Placebo

  • Experimental
    Active

    HE3286 10 mg (5 mg BID)

    Drug: HE3286

Interventions

  • DrugHE3286

    HE3286 10 mg per day (5 mg BID)

  • DrugPlacebo

    Placebo capsules BID

06

What researchers measure

Primary outcomes

  1. To evaluate the change in HbA1c from baseline to week 12 in the HE3286 treated group when compared to the placebo group.

    Time frame: 12-weeks

  2. To evaluate the safety and tolerance of HE3286 10 mg per day (5 mg BID) compared to placebo from baseline to week 12.

    Time frame: 12-weeks

Secondary outcomes

  1. To evaluate the effect of HE3286 on fasting blood glucose over time.

    Time frame: 12-weeks

  2. To evaluate the effect of HE3286 on insulin sensitivity over time.

    Time frame: 12-weeks

07

Study locations

22 sites
  • Anaheim, California 92801, United States
  • Anaheim, California 92805, United States
  • Beverly Hills, California 90211, United States
  • Buena Park, California 90620, United States
  • Burbank, California 91505, United States
  • Carmichael, California 95608, United States
  • Escondido, California 92025, United States
  • Fresno, California 93726, United States
  • Huntington Park, California 90255, United States
  • Long Beach,, California 90806, United States
  • Los Angeles, California 90057, United States
  • National City, California 91950, United States
  • Roseville, California 95661, United States
  • Chicago, Illinois 60616, United States
  • Baton Rouge, Louisiana 70808, United States
  • St. Louis, Missouri 63141, United States
  • Las Vegas, Nevada 89106, United States
  • Las Vegas, Nevada 89148, United States
  • El Paso, Texas 79905, United States
  • San Antonio, Texas 78229, United States
  • Salt Lake City, Utah 84107, United States
  • Kenosha, Wisconsin 53142, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2008, a primary completion of Jan 2010 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 6, 2008
First posted
Jun 10, 2008
Start
Jun 2008
Primary completionActual
Jan 2010
CompletionActual
Jan 2010
Last update
Jun 14, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 14, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00694057
Lead sponsor
Harbor Therapeutics
First posted
Jun 10, 2008
Start date
Jun 2008
Primary completion
Jan 2010
Completion
Jan 2010
Last update
Jun 14, 2011

Study contacts

Dwight R. Stickney, MD
study director · Harbor Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bezisterim

Start the discussion